Update on immunotherapy in the management of gallbladder cancer

Papers of special note have been highlighted as: • of interest

References

• 1. Strom BL, Soloway RD, Rios-Dalenz JL et al. Risk factors for gallbladder cancer. An international collaborative case–control study. Cancer 76(10), 1747–1756 (1995).
  Medline CASGoogle Scholar
• 2. Lazcano-Ponce EC, Miquel JF, Muñoz N et al. Epidemiology and molecular pathology of gallbladder cancer. CA. Cancer J. Clin. 51(6), 349–364 (2001).
  Medline CASGoogle Scholar
• 3. Chijiiwa K, Sumiyoshi K, Nakayama F. Impact of recent advances in hepatobiliary imaging techniques on the preoperative diagnosis of carcinoma of the gallbladder. World J. Surg. 15(3), 322–327 (1991).
  Medline CASGoogle Scholar
• 4. Duffy A, Capanu M, Abou-Alfa GK et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J. Surg. Oncol. 98(7), 485–489 (2008).
  Medline CASGoogle Scholar
• 5. Oertli D, Herzog U, Tondelli P. Primary carcinoma of the gallbladder: operative experience during a 16 year period. Eur. J. Surg. Acta Chir. 159(8), 415–420 (1993).
  Medline CASGoogle Scholar
• 6. Cheng H, Zhou D, Wang S, Ding J, Ma F. The immunological characteristics of gallbladder carcinoma and advances in immunotherapy practices. Biosci. Trends. 15(1), 9–15 (2021).
  Medline CASGoogle Scholar
• 7. Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann. Surg. 232(4), 557–569 (2000).
  Medline CASGoogle Scholar
• 8. Aloia TA, Járufe N, Javle M et al. Gallbladder cancer: expert consensus statement. HPB. 17(8), 681–690 (2015).
  Google Scholar
• 9. Yamaguchi K, Chijiiwa K, Ichimiya H et al. Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Arch. Surg. Chic. Ill 1960. 131(9), 981–984; discussion 985 (1996).
  CASGoogle Scholar
• 10. Abramson MA, Pandharipande P, Ruan D et al. Radical resection for T1b gallbladder cancer: a decision analysis. HPB. 11(8), 656–663 (2009).
  Google Scholar
• 11. Kwon W, Kim H, Han Y et al. Role of tumour location and surgical extent on prognosis in T2 gallbladder cancer: an international multicentre study. Br. J. Surg. 107(10), 1334–1343 (2020).
  Medline CASGoogle Scholar
• 12. Primrose JN, Fox R, Palmer DH et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J. Clin. Oncol. 35(Suppl. 15), 4006 (2017).
  Google Scholar
• 13. Edeline J, Bonnetain F, Phelip JM et al. Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J. Clin. Oncol. 35(Suppl. 4), 225 (2017).
  Google Scholar
• 14. Shroff RT, Kennedy EB, Bachini M et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. J. Clin. Oncol. 37(12), 1015–1027 (2019).
  MedlineGoogle Scholar
• 15. Ben-Josef E, Guthrie KA, El-Khoueiry AB et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J. Clin. Oncol. 33(24), 2617–2622 (2015).
  Medline CASGoogle Scholar
• 16. Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer – a systematic review. Eur. J. Surg. Oncol. 45(2), 83–91 (2019).
  MedlineGoogle Scholar
• 17. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273–1281 (2010).
  Medline CASGoogle Scholar
• 18. Sharma A, Kalyan Mohanti B, Pal Chaudhary S et al. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial. Eur. J. Cancer 123, 162–170 (2019).
  Medline CASGoogle Scholar
• 19. Kim ST, Kang JH, Lee J et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann. Oncol. 30(5), 788–795 (2019).
  Medline CASGoogle Scholar
• 20. Tsavaris N, Kosmas C, Gouveris P et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest. New Drugs 22(2), 193–198 (2004).
  Medline CASGoogle Scholar
• 21. Patt YZ, Hassan MM, Aguayo A et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101(3), 578–586 (2004).
  Medline CASGoogle Scholar
• 22. Lamarca A, Palmer DH, Wasan HS et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22(5), 690–701 (2021).
  Medline CASGoogle Scholar
• 23. Yoo C, Kim K-P, Jeong JH et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 22(11), 1560–1572 (2021).
  Medline CASGoogle Scholar
• 24. Takeda K, Kojima Y, Uno T et al. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J. Immunol. Baltimore. 184(10), 5493–5501 (2010).
  Medline CASGoogle Scholar
• 25. Mao W, Deng F, Wang D, Gao L, Shi X. Treatment of advanced gallbladder cancer: a SEER-based study. Cancer Med. 9(1), 141–150 (2020).
  MedlineGoogle Scholar
• 26. Malik IA, Aziz Z, Zaidi SHM, Sethuraman G. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am. J. Clin. Oncol. 26(2), 174–177 (2003).
  Medline CASGoogle Scholar
• 27. Meyerhardt JA, Zhu AX, Stuart K et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig. Dis. Sci. 53(2), 564–570 (2008).
  Medline CASGoogle Scholar
• 28. Oh D-Y, He AR, Qin S et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J. Clin. Oncol. 40(Suppl. 4), 378 (2022).
  Google Scholar
• 29. Oh D-Y, Ruth HA, Qin S et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1(8), EVIDoa2200015 (2022).
  MedlineGoogle Scholar
• 30. US FDA. FDA approves durvalumab for locally advanced or metastatic biliary tract cancer (2022). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer • The preceding two references are of considerable interest because they showcase the TOPAZ-1 clinical trial and its results, which led to US FDA approval in September 2022 of durvalumab in combination with gemcitabine and cisplatin in patients with advanced billiary tract cancer (BTC), including patients with gallbladder cancer
  Google Scholar
• 31. Lamarca A, Palmer DH, Wasan HS et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22(5), 690–701 (2021).
  Medline CASGoogle Scholar
• 32. Le DT, Durham JN, Smith KN et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017).
  Medline CASGoogle Scholar
• 33. US FDA. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication
  Google Scholar
• 34. Silva VWK, Askan G, Daniel TD et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin. Clin. Oncol. 5(5), 62 (2016).
  MedlineGoogle Scholar
• 35. Kim RD, Chung V, Alese OB et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 6(6), 888–894 (2020).
  MedlineGoogle Scholar
• 36. Klein O, Kee D, Nagrial A et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 6(9), 1405–1409 (2020).
  MedlineGoogle Scholar
• 37. Haslauer T, Greil R, Zaborsky N, Geisberger R. CAR T-cell therapy in hematological malignancies. Int. J. Mol. Sci. 22(16), 8996 (2021).
  Medline CASGoogle Scholar
• 38. Guo Y, Feng K, Liu Y et al. Phase I study of chimeric antigen receptor–modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24(6), 1277–1286 (2018).
  Medline CASGoogle Scholar
• 39. Kobayashi M, Sakabe T, Abe H et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J. Gastrointest. Surg. 17(9), 1609–1617 (2013).
  MedlineGoogle Scholar
• 40. Yashima Y, Sato S, Kawai T et al. Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. Hepatol. Int. 9(1), 142–148 (2015).
  MedlineGoogle Scholar
• 41. Merck Sharp, Dohme LLC. A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. (2019). https://clinicaltrials.gov/ct2/show/NCT04003636
  Google Scholar
• 42. European Organisation for Research and Treatment of Cancer. Open-label first line, single-arm phase II study of cisgem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer (2017). https://clinicaltrials.gov/ct2/show/NCT03260712 • This reference introduces the ongoing clinical trial of pembrolizumab and gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable BTC including GBC.
  Google Scholar
• 43. Knudson KM, Hicks KC, Luo X et al. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology 7(5), e1426519 (2018).
  MedlineGoogle Scholar
• 44. EMD Serono Research & Development Institute, Inc. A phase II/III, multicenter, randomized, placebo-controlled study of gemcitabine plus cisplatin with or without bintrafusp alfa (M7824) as first-line treatment of biliary tract. https://clinicaltrials.gov/ct2/show/NCT04066491
  Google Scholar
• 45. AIO-Studien-gGmbH. A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladder carcinoma (IMMUCHEC) (2018). https://clinicaltrials.gov/ct2/show/NCT03473574
  Google Scholar
• 46. Chen X, Wu X, Wu H et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J. Immunother. Cancer 8(2), (2020). https://pubmed.ncbi.nlm.nih.gov/33172881/ • This reference is of interest because it introduces the ongoing clinical trial of durvalumab and tremelimumab with gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naive patients with cholangio- and gallbladder carcinoma.
  Google Scholar
• 47. Chen X, Qin S, Gu S et al. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial. Int. J. Cancer 149(11), 1944–1954 (2021).
  Medline CASGoogle Scholar
• 48. Li W, Yu Y, Xu X et al. Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: update analytic results of an open-label phase II clinical study (JS001-ZS-BC001). J. Clin. Oncol. 39(Suppl. 15), e16170 (2021).
  Google Scholar
• 49. Jingjing L, Qi X, Wei Q et al. A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC. J. Clin. Oncol. 40(Suppl. 16), 4100 (2022).
  Google Scholar
• 50. Kuang M. Adjuvant immunotherapy combined with chemoradiation for patients with high-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer: a phase II, multicenter, randomized controlled trial (2020). https://clinicaltrials.gov/ct2/show/NCT04333927
  Google Scholar
• 51. AIO-Studien-gGmbH. A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladder carcinoma (IMMUCHEC) (2018). https://clinicaltrials.gov/ct2/show/NCT03473574
  Google Scholar
• 52. Liu T. A single-arm, single-center, prospective clinical study of the efficacy and safety of chemotherapy combined with toripalimab in the treatment of advanced biliary tract cancer (2019). https://clinicaltrials.gov/ct2/show/NCT03796429
  Google Scholar
• 53. Kuang M. Adjuvant immunotherapy combined with chemoradiation for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: a phase II, multicenter, randomized controlled trial (2020). https://clinicaltrials.gov/ct2/show/NCT04333927
  Google Scholar
• 54. Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer (2022). https://clinicaltrials.gov/ct2/show/NCT05239169
  Google Scholar
• 55. Yoo C. Randomized phase 2 study of preoperative gemcitabine plus cisplatin with or without durvalumab (MEDI4736) followed by postoperative durvalumab (MEDI4736) in patients with localized biliary tract cancer (2020). https://clinicaltrials.gov/ct2/show/NCT04308174
  Google Scholar